Breaking AI & Tech News Analyzed

The Lead Doctors, scientists, and researchers shared new research about ways to tackle cancer at the 2026 American Society of Clinical Oncology (Asco) annual meeting, the world's largest cancer conference. Breakthroughs in Cancer Treatment The event in Chicago, attended by 40,000 health professionals, featured more than 200 sessions and 2,700 poster presentations on this year's theme, “the science and practice of translation: improving cancer outcomes worldwide”. Smart Drugs in Cancer Treatment Researchers have developed a smart drug that stops cancer cells hiding. The experimental tablet, GRWD5769, can help shrink tumours by at least 30% in six of the world’s most common forms of the disease, delegates in Chicago were told. 26 of 83 patients with cervical, bladder, liver, bowel, lung or head and neck cancers who were given GRWD5769 alongside cemiplimab had tumour reductions of at least 30%. 15 had tumour reductions of at least 30%. A Daily Pill for Pancreatic Cancer A pill that doubles survival time in patients with pancreatic cancer was presented at the conference. In a trial of 500 patients, all of whom had pancreatic cancer that had spread, the pill, daraxonrasib, doubled survival time, with fewer side-effects compared with chemotherapy. Patients who took the drug lived substantially longer, for an average of 13.2 months, compared with 6.6 to 6.7 months for patients who had chemotherapy. Safely Skipping Some Treatments Some patients can safely skip some treatments, according to research presented at the conference. A genomic test could pave the way for a new era of personalised medicine, enabling doctors to determine which patients can safely skip chemotherapy. The Optima trial, led by University College London, followed 4,000 patients with newly diagnosed breast cancer in the UK, Norway, Sweden, Australia, New Zealand and Thailand. Those with a low score on the genomic test could be treated safely with hormone therapy alone. The Future of Cancer Treatment Urgent action is required to cope with rising cancer cases. The world faces a cancer workforce crisis, experts said, with a shortage of 100 million staff expected by 2050 when 100,000 people will be being diagnosed every day. A 21% increase in cancer incidence is predicted, according to a report presented at the conference. The rate is set to rise from 165 per 100,000 people in 2025 to 200 per 100,000 in 2050.

GLP‑1 Medications Show Promise in Reducing Breast Cancer IncidenceRecent analyses presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago suggest that patients using GLP‑1 receptor agonists—a class of weight‑loss drugs—experienced a 30% lower likelihood of being diagnosed with breast cancer compared with non‑users.Study cohort: 110,000 women aged 45‑80.Risk reduction: 30% for breast cancer onset.Lead researcher: Dr Elizabeth McDonald, University of Pennsylvania.Adjunctive Use of GLP‑1 Drugs Cuts Breast Cancer MortalityA separate investigation involving 27,000 breast‑cancer patients in Italy reported that adding a GLP‑1 agent to standard therapy was associated with a 30% decrease in cancer‑related death.Institution: IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola.Outcome: 30% lower mortality risk.Broad Cancer‑Spread Benefits Observed Across Multiple Tumor TypesData from the Cleveland Clinic, covering 12,000 patients with breast, lung, colorectal or liver cancer, indicated a 38‑50% reduction in progression to stage‑four disease among GLP‑1 users.Study size: 12,000 patients.Risk reduction range: 38%–50% for metastatic spread.Why These Findings Matter for Public Health and OncologyThe consistency of risk‑reduction signals across incidence, mortality and metastasis points to a potential paradigm shift: drugs originally designed for diabetes and obesity may become adjunct tools in cancer prevention and treatment. If confirmed, the impact could be substantial given the prevalence of obesity and the high incidence of breast cancer worldwide.Next Steps: Clinical Trials and Regulatory ConsiderationsExperts caution that the current evidence is observational. Ongoing randomized controlled trials will be needed to disentangle the effects of weight loss from direct pharmacologic actions of GLP‑1 agonists. Regulatory bodies may eventually evaluate these agents for oncologic indications, pending robust trial data.

The Rise of Sound Baths Sound baths, a wellness trend where participants lie down or sit while practitioners play instruments like gongs and singing bowls, have become increasingly popular. Proponents claim that these experiences can "soothe and calm your nervous system" and promote "healing" through specific sound frequencies. Can Sound Baths Really Relax Us? Research suggests that sound baths can have a positive impact on mood and stress levels. A 2016 study found that participants who took part in a meditation session involving Tibetan singing bowls reported feeling less tension, anger, and fatigue. Another study linked Tibetan sound meditation to improved cognitive function and mental health in breast cancer patients. The Science Behind Sound and Emotion Experts agree that the effects of sound on wellbeing are largely related to how we perceive and interpret those sounds, rather than specific types or frequencies. Our breathing can synchronise with beats we hear, a phenomenon known as "rhythmic entrainment," and music can induce different emotions such as happiness, sadness, and fear. A Nice Experience or Music Therapy? While sound baths can be a "nice experience," experts caution that they should not be confused with music therapy, a regulated profession that uses music listening or production to improve psychological and physical health. Music therapists work with a range of clients, including in schools and hospitals, and there is no single equivalent regulatory body for sound bath practitioners. The Verdict In conclusion, while sound baths may have some benefits, experts agree that their effects can be overstated. Focusing on one thing and trying to quiet the mind is key to their potential benefits. As with any wellness trend, it's essential to approach sound baths with a critical and nuanced perspective.

The Breakthrough in Breast Cancer TreatmentA landmark international study has revealed that millions of women with breast cancer could safely skip chemotherapy thanks to a genomic test that determines who needs the treatment and who doesn't. The randomised trial specifically examined whether the test could identify patients who would not benefit from chemotherapy, allowing them to avoid the potentially debilitating treatment without compromising their outcomes.The Scientific Evidence Behind the TestThe results of the Optima trial, which will be presented at the American Society of Clinical Oncology's annual meeting, are being hailed by experts as gamechanging. The five-year cancer-free survival rate was 93.7% in the group that skipped chemotherapy, which was statistically non-inferior to the 94.9% rate in patients randomly assigned to receive chemotherapy.The Prosigna genomic test analyzes the activity of 50 specific genes in tumor tissue to determine the molecular subtype and develops a risk of recurrence score to help doctors decide if chemotherapy is necessary. This precision medicine approach allows for personalized treatment decisions based on the unique characteristics of each patient's cancer.A Patient's Journey to Avoiding ChemotherapyKaren Bonham, a speech and language therapist from Swansea in Wales, was one of 4,429 patients with breast cancer recruited to the trial from countries including the UK, Norway, Sweden, Australia, New Zealand and Thailand. Diagnosed with cancer in 2017 at the age of 55 after routine breast screening, Bonham described the news as shocking."It certainly propels you into a world of uncertainty. Life priorities realign – you simply want to survive," she said. Dreading chemotherapy, she agreed to join the Optima trial after undergoing surgery. She was only days away from starting treatment and had already cut her hair short when the results came back in September 2017.While taking a walk on a Welsh beach, Bonham received a phone call from her hospital informing her she had been allocated to the group of patients that would not be having chemotherapy. "How to describe the initial feeling? Immense relief? Like Christmas? Certainly a mixture of the two," she said.The Future of Personalized Cancer CareToday, Bonham, now 64, retired and living in Cardiff, is free of cancer, healthy and shows no signs of the disease coming back. "It is coming up to nine years since my diagnosis," she said. "I am mindful of my diagnosis, alert to potential changes in my body but do not feel defined by [it]. I walk, enjoy yoga and live well."While not every woman with breast cancer will be able to skip chemotherapy—the treatment remains necessary and important for many—the trial results suggest that genomic testing can safely identify those who can avoid it. This approach represents a significant shift toward personalized medicine in oncology, reducing unnecessary treatment and its associated side effects while maintaining excellent outcomes."I hope that the trial will bring positive patient outcomes to many," Bonham said, reflecting on the potential impact of this research on future breast cancer patients.

Scientists from University College London and partners have proved that a 50‑gene genomic test can reliably pinpoint hormone‑positive breast‑cancer patients who do not need chemotherapy, potentially sparing millions from toxic side‑effects.Optima Trial Demonstrates Genomic Test Can Identify Low‑Risk PatientsThe Optima trial enrolled 4,429 women aged 40+ across the UK, Norway, Sweden, Australia, New Zealand and Thailand. Participants were split into a standard‑care arm (chemotherapy + hormone therapy) and a test‑guided arm where treatment was decided by the genomic score.Trial Numbers Reveal Near‑Identical Survival RatesFive‑year outcomes were strikingly similar:95% of patients receiving chemotherapy remained alive and recurrence‑free.94% of patients who skipped chemotherapy (low‑score group) were also alive and recurrence‑free.The test classified patients using a score derived from the activity of 50 tumour genes, produced by Veracyte's Prosigna assay.These figures indicate that for low‑score patients, chemotherapy adds little or no survival benefit.Potential Shift in Breast Cancer Treatment GuidelinesProf Rob Stein, chief investigator, says the results “address a longstanding challenge” by moving decision‑making from clinical features to tumour biology. Health systems could see reduced drug costs, fewer hospital visits, and a dramatic drop in chemotherapy‑related toxicity.Future Adoption and Healthcare SavingsWith funding from the NIHR, Veracyte and cancer charities, the study paves the way for rapid guideline updates at bodies like ASCO and NICE. Wider implementation could translate into billions of dollars saved globally and improve quality of life for countless patients. Ongoing monitoring will confirm long‑term outcomes, but the early data suggest a new era of personalised, cost‑effective breast‑cancer care.

Snapshot of Kingfisher’s Audiobook AppealThe Guardian’s review frames *Kingfisher* as a smart, reflective audiobook that delves into an unconventional romance while interrogating power dynamics and familial trauma. Narrated by Dan Bottomley, the 6hr 1min production offers listeners a lyrical journey through the protagonist’s obsession and the poet’s fragile world.Plot and Character Dynamics UnpackedThe story follows an unnamed creative‑writing academic who becomes infatuated with an Irish poet, seventeen years his senior and celebrated for her bird‑themed novels. Their meetings on a riverbank bench evolve from casual lunches to a caregiving partnership when the poet is diagnosed with breast cancer, contrasting sharply with the protagonist’s strained relationship with his mother, Hetty, and his long‑term partner, Michael.Unnamed academic – narrator and central viewpoint.Irish poet – the object of desire, author of bird stories.Michael – gym‑owner boyfriend, representing the protagonist’s ordinary life.Hetty – mother whose disapproval of her son’s sexuality adds familial tension.Runtime and Production MetricsThe audiobook runs 6 hours 1 minute, a length that allows for deep immersion without overstaying its narrative arc. Dan Bottomley’s narration is praised for its deft guidance, balancing the novel’s lyrical prose with the emotional weight of the characters’ experiences.Literary and Societal Implications of the StoryBeyond its plot, *Kingfisher* offers a fresh perspective on age‑gap relationships, positioning desire as a conduit for both empowerment and vulnerability. The review notes the novel’s commentary on parental influence, particularly how Hetty’s disapproval shapes the protagonist’s identity and choices, echoing broader conversations about LGBTQ+ acceptance and intergenerational trauma.Future Prospects for Rozie Kelly and Age‑Gap NarrativesHaving been shortlisted for this year’s Women’s Prize for Fiction, Kelly’s debut positions her as a compelling new voice in contemporary literature. The Guardian suggests that her nuanced handling of love, power, and caregiving could set a precedent for more complex age‑gap stories, and anticipates heightened interest in her next project, whether in print or audio format.

The Revelation of a Second Cancer Diagnosis Kylie Minogue has revealed that in early 2021 she was diagnosed with cancer for a second time, after diagnosis and successful treatment for breast cancer in 2005. Details of the Diagnosis and Treatment The pop star discussed the previously unannounced diagnosis in a new Netflix documentary entitled Kylie, available from today. “My second cancer diagnosis was in early 2021. I was able to keep that to myself … Not like the first time,” she said, referring to her highly publicised first treatment. 2005: Diagnosed with breast cancer, treated and given the all-clear. 2021: Diagnosed with cancer for a second time, kept private. The Impact on Her Life and Music Minogue said that after her treatment, she struggled “to find the right time” to announce it publicly, including after the huge success of her Grammy-winning 2023 single Padam Padam. “I don’t feel obliged to tell the world, and actually I just couldn’t at the time because I was just a shell of a person,” she said. “I didn’t want to leave the house again at one point. Padam Padam opened so many doors for me but on the inside I knew that cancer wasn’t just a blip in my life. And I really just wanted to say what happened so I can let go of it. I’d sit through interviews and every opportunity I thought, ‘now’s the time’, but I kept it to myself.” The Netflix Documentary The new Netflix documentary is in three parts, and directed by Michael Harte, who edited Netflix’s successful four-part documentary on David Beckham. As well as Minogue, it features interviews with her sister Dannii, and former duet partners Jason Donovan and Nick Cave, among others. The Importance of Check-Ups Minogue added in the promotional materials accompanying the launch: “There are so many people for whom cancer is part of their life and, I get it; you just want to move on and put it in the past or park it to the side. But, check-ups are incredibly important. It can be daunting and triggering but please be mindful of just how vital they are - and reach out for help if you need it, you’re not alone.”

The Lead: Perry's Raw Return to Center Stage Linda Perry, the iconic singer-songwriter behind 4 Non Blondes and hitmaker for stars like Christina Aguilera and Pink, is stepping back into the spotlight after years working behind the scenes. Her new documentary "Linda Perry: Let It Die Here" and accompanying album capture her journey through breast cancer, the death of her abusive mother, and her complex emotional landscape as she reclaims her artistic identity. The Event Details: Cancer, Loss, and Creative Resilience The documentary, directed by Don Hardy who had been filming Perry at work, captures her just over a week after a double mastectomy, walking gingerly into her studio while carrying surgical drains she calls "blood grenades." As Perry recovered from surgery, her elderly mother—who had physically and mentally abused her as a child—became ill and died three months later. Perry took her mother into her home for her final months, setting up a bed next to hers, reflecting that "the best gift my mom gave me was a peaceful death." The Creative Process: From Personal Pain to Artistic Expression Perry's new solo album, her first in 27 years, is a visceral, propulsive work about her mother's death and the complex feelings it unearthed. Songs include "I Am Daughter," "Now That She's Gone," "Liberation," and "What Lies With You," in which she calls her mother "the villain and the muse." The documentary shows Perry's songwriting prowess in action as she jams with Dolly Parton and Kate Hudson, while also capturing her hosting an event at South By Southwest for EqualizeHer, an organization she co-founded to promote gender equality in the music industry. The Industry Impact: A Voice for Gender Equality Perry has long been an advocate for gender equity in music. Early in her career, she was famously denied a producer credit on "What's Up," the track that sent 4 Non Blondes stratospheric. She let it go at the time but vowed it would never happen again. Through EqualizeHer and her own experiences, Perry continues to challenge the industry's gender disparities. The documentary also captures her re-formed 4 Non Blondes performing at the BottleRock festival, where she insisted on performing new material rather than just their old hits, stating "I want to play something new." The Personal Journey: Confronting Trauma and Finding Strength The documentary offers intimate glimpses into Perry's personal struggles, including a scene where she's captured dancing goofily in her closet to Supertramp's "Take the Long Way Home," which triggers deep emotional release. Another powerful moment shows her ripping open her shirt during a photoshoot in the desert to reveal her surgical scars, describing it as "ad-lib, a kind of a 'fuck-it' moment" that felt powerful afterward. Perry admits she's a workaholic who finds safety in creating: "Like most people who are in trauma, I am afraid to be left alone. Creating, working and music is where I feel safe." The Future Outlook: New Music and Continued Advocacy Perry's re-formed 4 Non Blondes are working on a new album due out early next year, based on material she wrote specifically for festival performances. She continues to collaborate with other artists, including Paris Jackson and Mike Campbell of Tom Petty's Heartbreakers. While the documentary was difficult for Perry to watch—"It was like watching a horror movie"—she recognizes its therapeutic value: "I think maybe the film helped me process and see something I didn't know I was doing." As she walks into the distance at the end of the documentary, Perry reflects: "Everything I've just experienced is going to change my life drastically. Life and death happened just now, so let's see what happens from here."

Angelina Jolie leads the new fashion‑driven drama Couture, bringing a rare level of personal honesty by confronting a storyline that mirrors her own double mastectomy performed to prevent breast cancer. While her performance is undeniably courageous, the film’s overall execution falls short of its ambitions.The plot follows Maxine, an American indie filmmaker (Jolie) who arrives in Paris to direct the opening short for a prestigious runway show. She discovers, through a compassionate doctor played by Vincent Lindon, that a recent biopsy confirms she has breast cancer, forcing her to consider postponing or abandoning her next project. Jolie conveys the shock and denial with subtlety, yet the script, penned by director Alice Winocour, often lapses into glib dialogue that undermines the emotional weight of the situation.Supporting characters include Ada, a fledgling South Sudanese model (Anyier Anei), makeup‑artist‑turned‑writer Angèle (Ella Rumpf), and the brooding first‑assistant director Anton (Louis Garrel). Their subplots—most notably Ada’s ankle injury that threatens the runway performance—remain underdeveloped, serving more as decorative set‑pieces than integral narrative threads.Visually, the film captures the glamour of Parisian haute couture with polished cinematography, yet this sheen accentuates the story’s lack of depth. The fashion world is presented with a “precious” aesthetic that feels specious, offering little insight beyond surface‑level allure.Despite these shortcomings, Jolie’s star power shines through. Her willingness to align a fictional role with a deeply personal health battle adds a layer of authenticity that the surrounding screenplay fails to sustain. ‘Couture’ will be available on digital platforms from 20 April, offering audiences a chance to appreciate Jolie’s performance even if the film’s broader ambitions remain unfulfilled.